Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이경은 | * |
dc.date.accessioned | 2016-12-06T02:12:26Z | - |
dc.date.available | 2016-12-06T02:12:26Z | - |
dc.date.issued | 2008 | * |
dc.identifier.issn | 0344-5704 | * |
dc.identifier.other | OAK-5005 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/233026 | - |
dc.description.abstract | Purpose: This open-label, multicenter phase II study was conducted to investigate the efficacy and safety of capecitabine plus gemcitabine combination chemotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. Patients and methods: We enrolled 63 patients who received capecitabine 830 mg/m2 orally twice daily on days 1-21 plus gemcitabine 1000 mg/m2 as a 30-min infusion on days 1, 8 and 15 every 4 weeks for up to six cycles. Results: A total of 14 patients had partial responses giving an overall response rate of 22% (95% confidence interval [CI] 13-34%) in the intent-to-treat population. The median time to progression and overall survival were 3.9 months (95% CI 3.5-5.7) and 7.5 months (95% CI 5.0-10.0), respectively, and 1-year survival rate was 27.1% in the intent-to-treat population. Capecitabine plus gemcitabine was well tolerated. Grade 3 hematological adverse events were neutropenia (21%) and thrombocytopenia (2%); the only grade 4 hematological events were anemia (2%) and neutropenia (6%). Non-hematological adverse events were mainly gastrointestinal events and hand-foot syndrome, which affected 16% of patients. Grade 3/4 non-hematological events were infrequent. Conclusion: The combination of capecitabine plus gemcitabine appears to be active and well tolerated as first-line treatment in patients with advanced/metastatic pancreatic cancer. © 2007 Springer-Verlag. | * |
dc.language | English | * |
dc.title | A phase II study of capecitabine plus gemcitabine in patients with locally advanced or metastatic pancreatic cancer | * |
dc.type | Article | * |
dc.relation.issue | 5 | * |
dc.relation.volume | 62 | * |
dc.relation.index | SCI | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.startpage | 763 | * |
dc.relation.lastpage | 768 | * |
dc.relation.journaltitle | Cancer Chemotherapy and Pharmacology | * |
dc.identifier.doi | 10.1007/s00280-007-0661-y | * |
dc.identifier.wosid | WOS:000258527900003 | * |
dc.identifier.scopusid | 2-s2.0-49749126800 | * |
dc.author.google | Song H.S. | * |
dc.author.google | Do Y.R. | * |
dc.author.google | Chang H.M. | * |
dc.author.google | Ryu M.H. | * |
dc.author.google | Lee K.H. | * |
dc.author.google | Kim Y.H. | * |
dc.author.google | Hong D.S. | * |
dc.author.google | Cho J.Y. | * |
dc.author.google | Lee K.E. | * |
dc.author.google | Kim S.Y. | * |
dc.contributor.scopusid | 이경은(7501517217;58364338700) | * |
dc.date.modifydate | 20240123091958 | * |